2 research outputs found
Soluble ICAM-1 levels in small-cell lung cancer: prognostic value for survival and predictive significance for response during chemotherapy
Intercellular adhesion molecule-1 (ICAM-1) is an adhesion molecule,
member of the immunoglobulin gene superfamily that seems to participate
in the evolution of the metastatic process. We investigated the
significance of baseline soluble ICAM-1 levels on the outcome of
patients with small-cell lung cancer and whether soluble ICAM-1 is a
predictive marker for objective response during and after chemotherapy
in patients with small-cell lung cancer. Fifty patients with recently
diagnosed small-cell lung cancer, as well as 27 healthy smokers, were
enrolled. Blood samples were collected at the time of diagnosis, during
and at the end of chemotherapy. Data were correlated with the
characteristics of the patients and survival as well as with ICAM-1
predictive role for objective response. Statistical significant values
of baseline soluble ICAM between patients and controls (p < 0.001) were
observed. Multivariate analysis revealed an elevated risk of death of 9
% in the first year after diagnosis for every 10 units of increased
soluble ICAM-1 at the baseline (p = 0.046). Performance status and
disease stage were also independent prognostic factors. Patients with
extensive disease who achieved an objective response during chemotherapy
showed a significant decrease (25.8 %) in their soluble ICAM-1 levels
compared with baseline levels (p = 0.001). Alongside performance status
and disease stage, baseline soluble ICAM-1 could be evaluated as an
additional prognostic factor in patients with small-cell lung cancer.
Also, a possible role for soluble ICAM-1 may exist as a predictive
marker for objective response during chemotherapy for patients with
extensive disease (p = 0.001)
Serum and Pleural Soluble Cell Adhesion Molecules in Mesothelioma Patients: A Retrospective Cohort Study
Mesothelioma, a malignant neoplasm of mesothelial cells, has overall poor prognosis. Cell adhesion molecules (CAMs) are proteins that contribute to the immune response. In this study the clinical utility and prognostic significance of serum and pleural fluid soluble CAM (sCAM) levels were assessed in patients with mesothelioma. Mesothelioma patients were retrospectively recruited (2016–2020). Clinical characteristics, serum and pleural sCAM levels (sE-cadherin, sE-selectin, intercellular adhesion molecule 1 (sICAM-1) and vascular cell adhesion molecule 1 (sVCAM-1)) and histopathological characteristics were gathered. A total of 51 healthy controls were also recruited for a secondary cross-sectional analysis. 92 mesothelioma patients were analyzed (mean age 64.5 years, 87% males, performance status 0–2). Patients with increased pleural sE-cadherin had higher risk for disease progression (adjusted HR 1.11 (1.02, 1.20), p = 0.013). Serum and pleural sE-selectin were decreased in patients with high-grade mesothelioma. Patients with increased serum or pleural sE-selectin levels had lower risk for death (adjusted HR 0.88 (0.81, 0.96), p = 0.003; 0.90 (0.82, 0.99), p = 0.039, respectively). Serum sE-cadherin, sE-selectin and sICAM-1 levels were significantly increased in mesothelioma patients compared to healthy controls. Further studies are needed to indicate the clinical utility of serum and pleural sCAMs in mesothelioma patients